Landscape Capital Management L.L.C. bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 9,197 shares of the company’s stock, valued at approximately $605,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. Jupiter Topco LLC purchased a new stake in BridgeBio Pharma in the 2nd quarter worth approximately $1,050,762,000. Janus Henderson Group PLC lifted its holdings in BridgeBio Pharma by 19.8% during the first quarter. Janus Henderson Group PLC now owns 13,179,013 shares of the company’s stock valued at $978,608,000 after purchasing an additional 2,178,556 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in BridgeBio Pharma during the second quarter valued at approximately $145,663,000. Pictet Asset Management Holding SA lifted its holdings in BridgeBio Pharma by 16.8% during the third quarter. Pictet Asset Management Holding SA now owns 1,690,829 shares of the company’s stock valued at $111,290,000 after purchasing an additional 242,703 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its position in shares of BridgeBio Pharma by 114.2% in the second quarter. Squarepoint Ops LLC now owns 1,191,732 shares of the company’s stock worth $88,760,000 after purchasing an additional 635,408 shares during the period. 99.85% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In related news, CEO Neil Kumar sold 10,000 shares of BridgeBio Pharma stock in a transaction that occurred on Wednesday, November 18th. The stock was sold at an average price of $77.72, for a total transaction of $777,200.00. Following the completion of the transaction, the chief executive officer directly owned 485,686 shares in the company, valued at approximately $37,747,515.92. This trade represents a 2.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of the company’s stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $72.85, for a total transaction of $145,700.00. Following the completion of the transaction, the chief accounting officer owned 120,687 shares of the company’s stock, valued at approximately $8,792,047.95. This trade represents a 1.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 56,980 shares of company stock worth $4,332,346 in the last quarter. Company insiders own 14.23% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on the company. Jefferies Financial Group reissued a “buy” rating on shares of BridgeBio Pharma in a report on Monday, October 5th. Mizuho upped their price objective on BridgeBio Pharma from $96.00 to $110.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 1st. Bank of America increased their target price on BridgeBio Pharma from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Piper Sandler increased their target price on BridgeBio Pharma from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday, October 19th. Finally, Wells Fargo & Company lifted their target price on BridgeBio Pharma from $98.00 to $102.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Nineteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, BridgeBio Pharma currently has a consensus rating of “Moderate Buy” and an average target price of $104.42.
Check Out Our Latest Research Report on BBIO
BridgeBio Pharma Price Performance
BBIO opened at $76.03 on Friday. BridgeBio Pharma, Inc. has a 12-month low of $62.50 and a 12-month high of $93.42. The business’s fifty day simple moving average is $70.30 and its 200-day simple moving average is $72.77.
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.12. The firm had revenue of $353.17 million during the quarter, compared to the consensus estimate of $293.47 million. During the same quarter in the prior year, the firm posted ($0.95) earnings per share. The business’s revenue for the quarter was up 192.6% compared to the same quarter last year. Equities analysts predict that BridgeBio Pharma, Inc. will post -2.55 earnings per share for the current fiscal year.
BridgeBio Pharma Profile
BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.
See Also
- Five stocks we like better than BridgeBio Pharma
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Want to see what other hedge funds are holding BBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report).
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
